Standard Biotools (LAB) EBT (2010 - 2026)

Standard Biotools (LAB) has reported EBT for 17 consecutive years, with -$21.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 17.25% year-over-year to -$21.4 million in Q2 2026; TTM through Jun 2026 was -$91.0 million, a 0.56% decrease from a year earlier, with the FY2025 full-year figure at -$96.7 million, down 6.97% from the prior year.
• EBT was -$21.4 million for Q2 2026 at Standard Biotools, down from -$14.6 million in the prior quarter.
• Over five years, EBT peaked at -$14.6 million in Q1 2026 and troughed at -$76.9 million in Q1 2022.
• A 5-year average of -$28.1 million and a median of -$21.9 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT slumped 275.08% in 2022 and jumped 78.43% in 2023, its largest moves.
• Over 5 years, EBT stood at -$20.8 million in 2022, then gained by 4.03% to -$19.9 million in 2023, then tumbled by 34.92% to -$26.9 million in 2024, then rose by 18.1% to -$22.0 million in 2025, then climbed by 2.71% to -$21.4 million in 2026.
• The last three EBT figures came in at -$21.4 million (Q2 2026), -$14.6 million (Q1 2026), and -$22.0 million (Q4 2025), per Business Quant data.